title: Intermittent preventive treatment using artemisinin-based combination therapy reduces malaria morbidity among school-aged children in Mali.
abstract: OBJECTIVE
  To assess the efficacy of intermittent preventive treatment (IPT) against malaria in school-aged children.
  
  
  METHODS
  This was an open randomized controlled trial of seasonal IPT among school children (IPTsc) aged 6-13 years in Kollé, Mali. The study began in September 2007 and completed follow-up in May 2008. Students were randomized to one of three study arms: Sulfadoxine-pyrimethamine plus artesunate (SP/AS), amodiaquine plus artesunate (AQ/AS) or vitamin C. All students received two full treatment doses, given 2 months apart during the season of high transmission from September to December. Groups were compared with respect to incidence of clinical malaria, asymptomatic parasitemia and haemoglobin concentration.
  
  
  RESULTS
  A total of 296 students were randomized, and retention in the study was 99.3%. Clinical malaria incidence in the SP/AS and AQ/AS arms was reduced by 66.6% and 46.5%, respectively, vs. vitamin C (P < 0.001). There were fewer clinic visits for any cause among the children receiving SP/AS or AQ/AS (P = 0.024). The prevalence of asymptomatic parasitemia was fivefold higher in the vitamin C arm than either SP/AS or AQ/AS at each post-treatment evaluation (P < 0.001). At the end of the transmission period, children treated with IPT had lower rates of anaemia (SP/AS, 17.7%; AQ/AS, 16.0%; vitamin C, 29.6%; P = 0.039).
  
  
  CONCLUSIONS
  IPT among school children reduced the rates of clinical malaria, all-cause acute clinic visits, asymptomatic parasitemia and anaemia among school-aged children.
authors.affiliation: University of Washington, Seattle, USA.
authors.forename: Breanna
authors.initials: B
authors.lastname: Barger
authors.forename: Hamma
authors.initials: H
authors.lastname: Maiga
authors.forename: Oumar Bila
authors.initials: OB
authors.lastname: Traore
authors.forename: Mamadou
authors.initials: M
authors.lastname: Tekete
authors.forename: Intimbeye
authors.initials: I
authors.lastname: Tembine
authors.forename: Antoine
authors.initials: A
authors.lastname: Dara
authors.forename: Zoumana Isaac
authors.initials: ZI
authors.lastname: Traore
authors.forename: Soren
authors.initials: S
authors.lastname: Gantt
authors.forename: Ogobara K
authors.initials: OK
authors.lastname: Doumbo
authors.forename: Abdoulaye A
authors.initials: AA
authors.lastname: Djimde
mesh_terms: D000293:Adolescent; D000740:Anemia / Q000517:prevention & control*; D037621:Artemisinins / Q000627:therapeutic use*; D000077332:Artesunate; D002648:Child; D004338:Drug Combinations; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D016778:Malaria, Falciparum / Q000188:drug therapy* / Q000453:epidemiology; D008297:Male; D008302:Mali / Q000453:epidemiology; D018512:Parasitemia / Q000517:prevention & control*; D011739:Pyrimethamine / Q000627:therapeutic use*; D013413:Sulfadoxine / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D037621:Artemisinins; D004338:Drug Combinations; C001205:fanasil, pyrimethamine drug combination; D000077332:Artesunate; D013413:Sulfadoxine; D011739:Pyrimethamine